title: What does serum fibroblast growth factor 23 do in hemodialysis patients?
abstract: Fibroblast growth factor 23 (FGF-23) is a phosphate-regulating substance largely produced by osteocytes. Its major action, in normal subjects, is the inhibition of Na-coupled reabsorption of inorganic phosphate in the renal proximal tubule. FGF-23 levels increase markedly in dialysis patients. Why do the FGF-23 levels increase in these patients, and do they have any physiologic or pathophysiologic effects?
authors: Department of Internal Medicine, Baylor University Medical Center, 3500 Gaston Avenue, Dallas, TX 75246, USA. m.emmett@baylorhealth.edu
authors: M
authors: M
authors: Emmett
mesh_terms: D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000097:blood* / Q000378:metabolism; D006801:Humans; D007684:Kidney Tubules / Q000378:metabolism*; D010710:Phosphates / Q000378:metabolism; D006435:Renal Dialysis
chemical_list: C000717427:FGF23 protein, human; D010710:Phosphates; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23